Skip to main content
SpringerLink
Log in

PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Pentraxin 3 (PTX3) is an acute-phase protein involved in C1q clearance. The presence of anti-C1q and the absence of anti-PTX3 antibodies were associated with lupus glomerulonephritis (LGLN). Our aim was to assess soluble and kidney-expressed PTX3 and their relationships with anti-C1q and anti-PTX3 antibodies in LGLN. Serum PTX3, anti-C1q, anti-dsDNA, and anti-PTX3 antibodies were tested in 130 systemic lupus erythematosus (SLE) patients, 130 healthy and 127 disease controls. Twenty-nine renal biopsies from SLE patients were analyzed and PTX3 immunostaining was quantified by morphometric analysis. Parametric and nonparametric statistics were performed. PTX3 serum levels were lower in SLE versus controls, but they were correlated with proteinuria in LGLN patients (p = 0.001). LGLN patients had higher anti-C1q and lower anti-PTX3 antibody levels than those without (p < 0.0001). LGLN was more prevalent in anti-C1q(+)/anti-PTX3(−) than in anti-C1q(+)/anti-PTX3(+) patients (p < 0.001). No LGLN was observed in anti-C1q(−)/anti-PTX3(+) patients. PTX3 was expressed in glomeruli and renal interstitium. Renal PTX3 was correlated with proteinuria (p = 0.024) and interstitial fibrosis (p = 0.023). PTX3 staining and fibrosis were higher in anti-PTX3(−) than anti-PTX3(+) patients. In conclusion, PTX3 is expressed in glomeruli of LGLN patients, primarily in anti-PTX3(−) patients, where it is correlated with renal fibrosis. Anti-C1q/anti-PTX3 antibody profile seems to be useful in LGLN assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706

    Article  PubMed  Google Scholar 

  2. Doria A, Zen M, Canova M et al (2010) SLE diagnosis and treatment: when early is early. Autoimmun Rev 10:55–60

    Article  CAS  PubMed  Google Scholar 

  3. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L (2014) Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 13:770–777

    Article  CAS  PubMed  Google Scholar 

  4. Rekvig OP, Putterman C, Casu C et al (2012) Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev 11:596–603

    Article  PubMed  Google Scholar 

  5. Pickering MC, Botto M (2010) Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol 6:490–493

    Article  CAS  PubMed  Google Scholar 

  6. Shoenfeld Y, Szyper-Kravitz M, Witte T et al (2007) Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N. Y. Acad Sci 1108:227–239

    Article  CAS  Google Scholar 

  7. Bassi N, Ghirardello A, Blank M et al (2010) IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 69:1704–1710

    Article  CAS  PubMed  Google Scholar 

  8. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Aanaya JM (2009) The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 39:38–54

    Article  CAS  PubMed  Google Scholar 

  9. Nauta AJ, de Haij S, Bottazzi B et al (2005) Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 67:543–553

    Article  CAS  PubMed  Google Scholar 

  10. Speeckaert MM, Speeckaert R, Carrero JJ, Vanholder R, Delanghe JR (2013) Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease. J Clin Immunol 33:881–890

    Article  CAS  PubMed  Google Scholar 

  11. Doria A, Gatto M (2012) Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus 21:1492–1496

    Article  CAS  PubMed  Google Scholar 

  12. American College of Rheumatology Ad Hoc on Systemic Lupus Erythematosus Response Criteria (2004) The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 50:3418–3426

    Article  Google Scholar 

  13. Weening JJ, D’Agati V, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. JASN 15:241–250

    Article  PubMed  Google Scholar 

  14. Bencivelli W, Vitali C, Isenberg DA et al (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity. The European consensus study group for disease activity in SLE. Clin Exp Rheumatol 10:549–554

    CAS  PubMed  Google Scholar 

  15. Ceol M, Tiralongo E, Baelde HJ et al (2012) Involvement of the tubular ClC-type exchanger ClC-5 in glomeruli of human proteinuric nephropathies. PLoS One 7:e45605

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Doria A, Amoura Z, Cervera R et al (2014) Annual direct medical costs of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 73:154–160

    Article  PubMed  Google Scholar 

  17. Yung S, Chan TM (2008) Anti-DNA antibodies in the pathogenesis of lupus nephritis—the emerging mechanisms. Autoimmun Rev 7:317–321

    Article  CAS  PubMed  Google Scholar 

  18. Linnik MD, Hu JZ, Heilbrunn KR et al (2005) Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 52:1129–1137

    Article  CAS  PubMed  Google Scholar 

  19. Matrat A, Veysseyre-Balter C, Trolliet P et al (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20:28–34

    Article  CAS  PubMed  Google Scholar 

  20. Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M (2011) Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 20:1267–1274

    Article  CAS  PubMed  Google Scholar 

  21. Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G (2009) Anti-C1q autoantibodies in lupus nephritis. Ann N. Y. Acad Sci 1173:47–51

    Article  CAS  Google Scholar 

  22. Orbai AM, Truedsson L, Sturfelt G et al (2015) Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24:42–49

    Article  CAS  PubMed  Google Scholar 

  23. Grootscholten C, Dieker JW, McGrath FD et al (2007) A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 66:693–696

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Katsumata Y, Miyake K, Kawaguchi Y et al (2011) Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 63:2436–2444

    Article  CAS  PubMed  Google Scholar 

  25. Bigler C, Hopfer H, Danner D, Schaller M, Mihatsch MJ, Trendelenburg M (2011) Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. Nephrol Dial Transplant 26:1220–1228

    Article  CAS  PubMed  Google Scholar 

  26. Gatto M, Zen M, Ghirardello A et al (2013) Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 12:523–526

    Article  CAS  PubMed  Google Scholar 

  27. Santer DM, Hall BE, George TC et al (2010) C1q deficiency leads to the defective suppression of INF-α in response to nucleoprotein containing immune complexes. J Immunol 185:4738–4749

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6:280–289

    Article  PubMed  Google Scholar 

  29. Bassi N, Zampieri S, Ghirardello A et al (2009) Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin Rev Allergy Immunol 37:36–43

    Article  CAS  PubMed  Google Scholar 

  30. Bottazzi B, Garlanda C, Cotena A et al (2009) The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 227:9–18

    Article  CAS  PubMed  Google Scholar 

  31. Nauta AJ, Bottazzi B, Mantovani A et al (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 33:465–473

    Article  CAS  PubMed  Google Scholar 

  32. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A (2008) Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 20:538–544

    Article  CAS  PubMed  Google Scholar 

  33. Bottazzi B, Vouret-Craviari V, Bastone A et al (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272:32817–32823

    Article  CAS  PubMed  Google Scholar 

  34. Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G (2003) The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 170:1466–1472

    Article  CAS  PubMed  Google Scholar 

  35. Hamad RR, Eriksson MJ, Berg E, Al Merri A, Al Suwaidi J (2012) Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand 91:50–56

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

All authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medicine - DIMED, Division of Rheumatology, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy

    Nicola Bassi, Anna Ghirardello, Mariele Gatto, Margherita Zen, Silvano Bettio, Luca Iaccarino, Leonardo Punzi & Andrea Doria

  2. Department of Medicine - DIMED, Division of Nephrology, University of Padova, Padova, Italy

    Dorella Del Prete & Monica Ceol

  3. Department of Biotechnology and Translational Medicine, University of Milano, Milano, Italy

    Alberto Mantovani

Authors
  1. Nicola Bassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorella Del Prete
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Ghirardello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mariele Gatto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Monica Ceol
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Margherita Zen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Silvano Bettio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alberto Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Luca Iaccarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Leonardo Punzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Andrea Doria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Doria.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bassi, N., Del Prete, D., Ghirardello, A. et al. PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. Clinic Rev Allerg Immunol 49, 217–226 (2015). https://doi.org/10.1007/s12016-015-8476-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-015-8476-9

Keywords

Search

Navigation